Is the Coronovac Vaccine Effective in Patients Receiving Chemotherapy
Conditions
Keywords
coronovac, covid-19
Brief summary
This study aimed to investigate the effectiveness of CoronaVac vaccine, which is more than 90% protective in healthy people, in cancer patients receiving active chemotherapy. In this study, to collect information to measure the amount of antibodies produced by the vaccine in the blood of volunteers with the CoronoVac vaccine and to compare it with healthy volunteers.
Interventions
BIOLOGICALCoronoVAC
SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
Sponsors
Asoc. Prof. Erdoğan Selçuk Şeber
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Group 1 1. 18 years old and above 2. Having completed two doses of CoronoVac vaccine on time 3. Those with a pathological diagnosis of breast cancer or lung cancer 4. Being the first dose of vaccine during active chemotherapy period 5. Ecog performance score 0-1 6. Patients who signed the informed voluntary consent form * Group 2 1. Over 18 years old 2. Ecog performance score is 0-1 3. Those who have completed 2 doses of coronovac vaccine within the recommended period 4. Volunteer who signed the informed consent form
Exclusion criteria
* For all groups 1. Being confirmed or suspected covid-19 before vaccination 2. Symptomatic covid-19 infection 3. Being addicted to alcohol or drugs 4. Having a fever of 37.8 ° C as a suspect before vaccination 5. Aspleni
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antibody levels above the defined cut-off | Between the third and sixth weeks after the second dose of vaccine | SARS-CoV-2 IgG II ≥ 50.0 AU/ml (positive) and SARSCoV- 2 IgM \>1 (positive) |
Countries
Turkey (Türkiye)
Outcome results
None listed